“Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price,” ADVI VP Lindsay Bealor Greenleaf explained to BioWorld about the costs of insulin

May 28, 2020 BACK TO RESOURCES

Written by Mari Serebrov

***excerpt***

“Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price”

***end excerpt***

View full article here